IDEAYA Biosciences Inc (NASDAQ:IDYA)
| 26.38 Delayed Data As of 3:59pm ET |  -0.81 / -2.98%Today’s Change | 12.02 Today|||52-Week Range 30.25 | +45.18% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Pharmaceuticals: Major | MARKET CAP $1.6B |
Company Description
IDEAYA Biosciences, Inc. engages in the research and development of oncology-focused precision medicine. The firm focuses on the targeted therapeutics for patients selected using molecular diagnostics. Its product candidate, IDE196, is a protein kinase C inhibitor for genetically-defined cancers having GNAQ or GNA11 gene mutations. The company was founded by Yujiro S. Hata and Jeffrey Hager in June 2015 and is headquartered in South San Francisco, CA.
Contact Information
IDEAYA Biosciences, Inc. 7000 Shoreline Court South San Francisco California 94080-1945 |
Employees
Shareholders
| Individual stakeholders | 8.07% |
| Other institutional | 50.29% |
| Mutual fund holders | 35.76% |
Top Executives
| Yujiro S. Hata | President, Chief Executive Officer & Director |
| Paul A. Stone | Chief Financial Officer & Executive Vice President |
| Paul A. Barsanti | Chief Technology Officer |
| Matthew Maurer | VP, Head-Medical Affairs & Clinical Oncology |
| Michael Anthony White | Chief Scientific Officer |
